Up next

Autoplay

Bendamustine/Rituximab as Induction Therapy in MCL

1 Views • 08/26/25
Share
Side Effects
Side Effects
Subscribers
0

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, The University of British Columbia, discusses a retrospective analysis evaluating bendamustine and rituximab as induction therapy in both transplant eligible and ineligible patients with mantle cell lymphoma.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Show more
0 Comments sort Sort By

Up next

Autoplay